{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:20:10Z","timestamp":1792718410726,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006458","name":"Children's Hospital of Philadelphia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009992","name":"Seattle Children's Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F30 5F30AI164574-02"],"award-info":[{"award-number":["F30 5F30AI164574-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA201135"],"award-info":[{"award-number":["5R01CA201135"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ymthe.2024.06.004","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T11:35:34Z","timestamp":1719920134000},"page":"2676-2691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Human plasma cells engineered to secrete bispecifics drive effective in\u00a0vivo leukemia killing"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-8327","authenticated-orcid":false,"given":"Tyler F.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnal","family":"Narvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine N.","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaiz","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Leiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Arlauckas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2302-7367","authenticated-orcid":false,"given":"Richard G.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.06.004_bib1","first-page":"669","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.06.004_bib2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T\u00a0cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib3","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2024.06.004_bib4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.004_bib5","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA Approval: Blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.06.004_bib6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a Bispecific T-cell Engager (BiTE(\u00ae)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ymthe.2024.06.004_bib7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations","volume":"36","author":"Toksvang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.06.004_bib8","doi-asserted-by":"crossref","first-page":"e895","DOI":"10.1016\/j.clml.2021.06.022","article-title":"Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System","volume":"21","author":"Apostolidou","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ymthe.2024.06.004_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs."},{"key":"10.1016\/j.ymthe.2024.06.004_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.004_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","article-title":"Glofitamab: First Approval","volume":"83","author":"Shirley","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.06.004_bib12","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2017.11.012","article-title":"Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells","volume":"26","author":"Hung","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.004_bib14","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1038\/s41467-022-33787-8","article-title":"Ex\u00a0vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in\u00a0vivo","volume":"13","author":"Cheng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.004_bib15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41419-020-03187-1","article-title":"Engineering of \u03b1-PD-1 antibody-expressing long-lived plasma cells by CRISPR\/Cas9-mediated targeted gene integration","volume":"11","author":"Luo","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2024.06.004_bib16","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00262-021-03101-4","article-title":"Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies","volume":"71","author":"Page","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2024.06.004_bib17","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/jth.13520","article-title":"Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in\u00a0vivo in NOD\/SCID\u03b3c-\/- mice","volume":"14","author":"Levy","year":"2016","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2024.06.004_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax0644","article-title":"B cells engineered to express pathogen-specific antibodies protect against infection","volume":"4","author":"Moffett","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib19","article-title":"Vaccine Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B Cells","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.004_bib20","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.42995","article-title":"Reprogramming the Antigen Specificity of B Cells Using Genome-Editing Technologies","volume":"8","author":"Voss","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2024.06.004_bib21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20190287","article-title":"HIV-specific humoral immune responses by CRISPR\/Cas9-edited B cells","volume":"216","author":"Hartweger","year":"2019","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2024.06.004_bib22","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41467-020-19649-1","article-title":"Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion","volume":"11","author":"Nahmad","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.004_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189991","article-title":"Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors","volume":"22","author":"Page","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.06.004_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.06.004_bib25","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.004_bib26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nbt.3964","article-title":"Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring","volume":"35","author":"Eyer","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/eji.1830160206","article-title":"Limiting dilution analysis of the B cell compartment in human bone marrow","volume":"16","author":"Hibi","year":"1986","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.775128","article-title":"Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities","volume":"12","author":"Marchand","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108733","article-title":"Plasma cell dynamics in the bone marrow niche","volume":"34","author":"Benet","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2024.06.004_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines6010022","article-title":"Targeting Leukemia Stem Cells in the Bone Marrow Niche","volume":"6","author":"Tasian","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2024.06.004_bib32","doi-asserted-by":"crossref","first-page":"9466","DOI":"10.1128\/jvi.71.12.9466-9474.1997","article-title":"Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells","volume":"71","author":"Robbins","year":"1997","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2018-99-109762","article-title":"A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE\u00ae) Antibody Construct, in Relapsed\/Refractory Acute Myeloid Leukemia (R\/R AML)","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.004_bib34","article-title":"SEC-seq: Association of molecular signatures with antibody secretion in thousands of single human plasma cells","author":"Cheng","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2024.06.004_bib35","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1182\/bloodadvances.2018025726","article-title":"Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.06.004_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020458","article-title":"Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory\/Relapsed Acute Lymphoblastic Leukemia","volume":"14","author":"Pawinska-Wasikowska","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2024.06.004_bib37","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T\u00a0cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.06.004_bib38","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","article-title":"CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis","volume":"44","author":"M\u00f8lh\u00f8j","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.06.004_bib40","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.170.8.4397","article-title":"T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-\/CD3- bispecific single-chain antibody construct","volume":"170","author":"Dreier","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib41","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3324\/haematol.2021.279410","article-title":"Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia","volume":"107","author":"Bride","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2024.06.004_bib42","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.004_bib43","first-page":"23","article-title":"Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy","volume":"14","author":"Franquiz","year":"2020","journal-title":"Biologics"},{"key":"10.1016\/j.ymthe.2024.06.004_bib44","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.06.004_bib45","article-title":"Human macrophages engineered to secrete a bispecific T\u00a0cell engager support antigen-dependent T\u00a0cell responses to glioblastoma","volume":"8","author":"Gardell","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2024.06.004_bib46","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.004_bib48","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.004_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.004_bib50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2024.06.004_bib51","series-title":"Management of Hypogammaglobulinaemia and B-Cell Aplasia","author":"Topp","year":"2022"},{"key":"10.1016\/j.ymthe.2024.06.004_bib52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib53","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.004_bib54","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.004_bib55","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ymthe.2018.03.001","article-title":"A Rapamycin-Activated Caspase 9-Based Suicide Gene","volume":"26","author":"Stavrou","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.004_bib56","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T\u00a0cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.06.004_bib57","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.004_bib58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T\u00a0cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.004_bib59","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.004_bib60","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.4049\/jimmunol.1501761","article-title":"Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition","volume":"198","author":"Arumugakani","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib61","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41467-017-01901-w","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.004_bib62","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1172\/JCI40231","article-title":"CD20 deficiency in humans results in impaired T\u00a0cell-independent antibody responses","volume":"120","author":"Kuijpers","year":"2010","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.06.004_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229170","article-title":"CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells","volume":"15","author":"Kozlova","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.06.004_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00026-22","article-title":"Persistence of Virus-Specific Antibody after Depletion of Memory B Cells","volume":"96","author":"Langley","year":"2022","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ajcp\/aqw151.007","article-title":"CD38 Expression Loss in Multiple Myeloma Treated with Daratumumab","volume":"146","author":"Hotchandani","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033534","article-title":"Mice deficient in CD38 develop an attenuated form of collagen type II-induced arthritis","volume":"7","author":"Postigo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.06.004_bib67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.HS9.0000843456.05456.f5","article-title":"S141: Eliciting anti-tumor t\u00a0cell activity in chronic lymphocytic leukemia with bispecific antibody-based combination therapy","volume":"6","author":"Papazoglou","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.ymthe.2024.06.004_bib68","first-page":"148","article-title":"Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"Pharm. Therapeut."},{"key":"10.1016\/j.ymthe.2024.06.004_bib69","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib70","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib71","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719894871","article-title":"Daratumumab in untreated newly diagnosed multiple myeloma","volume":"10","author":"Abdallah","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib72","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3324\/haematol.2019.242453","article-title":"Bi38-3 is a novel CD38\/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma","volume":"106","author":"Fayon","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2024.06.004_bib73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2024.06.004_bib74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/jfmpc.jfmpc_578_19","article-title":"Trends in FDA drug approvals over last 2 decades: An observational study","volume":"9","author":"Batta","year":"2020","journal-title":"J.\u00a0Fam. Med. Prim. Care"},{"key":"10.1016\/j.ymthe.2024.06.004_bib75","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/GIM.0b013e318133fb1b","article-title":"The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"9","author":"Clarke","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2024.06.004_bib76","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MBC.0000000000000885","article-title":"Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B","volume":"31","author":"Chhabra","year":"2020","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.ymthe.2024.06.004_bib77","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I","volume":"6","author":"Jameson","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymthe.2024.06.004_bib78","first-page":"463","article-title":"Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease","volume":"15","author":"Cornillie","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.004_bib79","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2125.2006.02581.x","article-title":"Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis","volume":"62","author":"Nestorov","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.06.004_bib80","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1592\/phco.31.9.896","article-title":"Liraglutide: clinical pharmacology and considerations for therapy","volume":"31","author":"Sisson","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ymthe.2024.06.004_bib81","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmech.2016.05.027","article-title":"Enfuvirtide-PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties","volume":"121","author":"Cheng","year":"2016","journal-title":"Eur. J. Med. Chem."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624003861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T02:52:19Z","timestamp":1763779939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624003861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1525001624003861"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.004","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human plasma cells engineered to secrete bispecifics drive effective in\u00a0vivo leukemia killing","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}